BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 3802099)

  • 1. Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients.
    Colcher D; Esteban JM; Carrasquillo JA; Sugarbaker P; Reynolds JC; Bryant G; Larson SM; Schlom J
    Cancer Res; 1987 Feb; 47(4):1185-9. PubMed ID: 3802099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiolabeled monoclonal antibody B72.3 localization in metastatic lesions of colorectal cancer patients.
    Colcher D; Carrasquillo JA; Esteban JM; Sugarbaker P; Reynolds JC; Siler K; Bryant G; Larson SM; Schlom J
    Int J Rad Appl Instrum B; 1987; 14(3):251-62. PubMed ID: 3667307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vivo application of monoclonal antibodies in the management of human carcinomas].
    Ohuchi N; Colcher D; Schlom J
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):1109-14. PubMed ID: 3291770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3.
    Esteban JM; Colcher D; Sugarbaker P; Carrasquillo JA; Bryant G; Thor A; Reynolds JC; Larson SM; Schlom J
    Int J Cancer; 1987 Jan; 39(1):50-9. PubMed ID: 3793270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue.
    Molinolo A; Simpson JF; Thor A; Schlom J
    Cancer Res; 1990 Feb; 50(4):1291-8. PubMed ID: 2297774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3.
    Colcher D; Milenic D; Roselli M; Raubitschek A; Yarranton G; King D; Adair J; Whittle N; Bodmer M; Schlom J
    Cancer Res; 1989 Apr; 49(7):1738-45. PubMed ID: 2924317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of monoclonal antibody B72.3 in the management of gynecologic malignancies.
    Simpson J; Schlom J
    Yale J Biol Med; 1988; 61(4):351-66. PubMed ID: 3055701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma.
    Colcher D; Esteban J; Carrasquillo JA; Sugarbaker P; Reynolds JC; Bryant G; Larson SM; Schlom J
    Cancer Res; 1987 Aug; 47(15):4218-24. PubMed ID: 3607761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct localization comparison of murine and chimeric B72.3 antibodies in patients with colon cancer.
    Meredith RF; Khazaeli MB; Grizzle WE; Orr RA; Plott G; Urist MM; Liu T; Russell CD; Wheeler RH; Schlom J
    Hum Antibodies Hybridomas; 1993 Oct; 4(4):190-7. PubMed ID: 8257773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.
    Maraveyas A; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA
    Cancer Res; 1995 Mar; 55(5):1060-9. PubMed ID: 7866989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraoperative radioimmunolocalization of colorectal carcinoma with a hand-held gamma probe and MAb B72.3: comparison of in vivo gamma probe counts with in vitro MAb radiolocalization.
    Tuttle SE; Jewell SD; Mojzisik CM; Hinkle GH; Colcher D; Schlom J; Martin EW
    Int J Cancer; 1988 Sep; 42(3):352-8. PubMed ID: 3417363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.
    Yokota T; Milenic DE; Whitlow M; Wood JF; Hubert SL; Schlom J
    Cancer Res; 1993 Aug; 53(16):3776-83. PubMed ID: 8339291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer.
    Colcher D; Milenic DE; Ferroni P; Carrasquillo JA; Reynolds JC; Roselli M; Larson SM; Schlom J
    J Nucl Med; 1990 Jul; 31(7):1133-42. PubMed ID: 2362192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoradiographic evaluation of radiolabeled monoclonal antibody B72.3 distribution in tumor and lymph nodes of adenocarcinoma patients.
    Roselli M; Hitchcock CL; Molinolo A; Milenic DE; Colcher D; Martin EW; Hinkle GH; Schlom J
    Anticancer Res; 1995; 15(3):975-84. PubMed ID: 7645989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of spatial configuration of carcinoma cell populations on the expression of a tumor-associated glycoprotein.
    Horan Hand P; Colcher D; Salomon D; Ridge J; Noguchi P; Schlom J
    Cancer Res; 1985 Feb; 45(2):833-40. PubMed ID: 3881173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo targeting properties of iodine-123- or iodine-131-labeled monoclonal antibody 14C5 in a non-small cell lung cancer and colon carcinoma model.
    Burvenich I; Schoonooghe S; Cornelissen B; Blanckaert P; Coene E; Cuvelier C; Mertens N; Slegers G
    Clin Cancer Res; 2005 Oct; 11(20):7288-96. PubMed ID: 16243799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake.
    Scott AM; Lee FT; Jones R; Hopkins W; MacGregor D; Cebon JS; Hannah A; Chong G; U P; Papenfuss A; Rigopoulos A; Sturrock S; Murphy R; Wirth V; Murone C; Smyth FE; Knight S; Welt S; Ritter G; Richards E; Nice EC; Burgess AW; Old LJ
    Clin Cancer Res; 2005 Jul; 11(13):4810-7. PubMed ID: 16000578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.